Analytical Data
-
Gene name
isaB
- Application
-
Alternative Names
isaB; Immunodominant staphylococcal antigen B
-
Species
Staphylococcus aureus
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9LAB5
-
Expression Region
37-175aa
-
Molecular Weight
20.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of isaB recombinant protein has gained significant attention due to its potential applications in biotechnology and medicine. IsaB, an essential component involved in the pathogenicity of various bacteria, plays a crucial role in biofilm formation and virulence. Understanding its structure and function can provide insights into the mechanisms of bacterial infections and resistance. Recombinant protein technology allows for the production of isaB in large quantities, enabling detailed biochemical studies and the development of targeted therapies. Researchers aim to explore the immunogenic properties of isaB to evaluate its potential as a vaccine candidate or as a target for novel antimicrobial agents. Additionally, the ability to manipulate the isaB gene offers opportunities for genetic engineering to devise strategies that could disrupt its function and mitigate bacterial infections. The growing prevalence of antibiotic resistance further underscores the urgency of this research, as innovative approaches, including the targeting of specific virulence factors like isaB, are imperative in the fight against resistant bacterial strains. Overall, the exploration of isaB recombinant protein is a promising avenue that intersects microbiology, immunology, and therapeutic development, aiming to enhance our understanding of bacterial pathogenesis and improve treatment options for infectious diseases.
